Taken together, our study demonstrates that co-targeting GITR and PD-1 during early TIL expansion markedly improves both the proliferative capacity and antitumor functionality of TILs, offering a promising strategy to enhance adoptive cell therapy for ovarian cancer. Here, TNFRSF18 is linked to ovarian cancer.